Table 3.
Summary of the clinical trials of Convalescent Plasma for treatment of COVID-19.
| Sr. no | Plasma intervention/treatment | Sponsor | Clinical phase (sample size) | Status | Clinical trial identifier |
|---|---|---|---|---|---|
| 1. | Convalescent Plasma from Recovered COVID-19 Donors | Hackensack Meridian Health, New Jersey, United States | Phase II (55) |
On-going | NCT04343755 |
| 2. | Convalescent Plasma from Recovered COVID-19 Donors | Erasmus Medical Center, Netherland | Phase II & III (426) |
On-going | NCT04342182 |
| 3. | Convalescent Plasma from Recovered COVID-19 Donors | Cristina Avendaño Solá, Spain | Phase II (278) |
On-going | NCT04345523 |
| 4. | Convalescent Plasma from Recovered COVID-19 Donors | King Fahad Specialist Hospital Dammam, Saudi Arabia |
Phase II (40) |
On-going | NCT04347681 |
| 5. | Convalescent Plasma from Recovered COVID-19 Donors | Centro de Hematología y Medicina Interna, Mexico | Phase II (10) |
On-going | NCT04357106 |
| 6. | Convalescent Plasma from Recovered COVID-19 Donors | University of Chicago, Illinois, United States | Phase I (10) |
On-going | NCT04340050 |
| 7. | Anti-SARS-CoV-2 Inactivated Convalescent Plasma recovered from COVID-19 Donors | Shanghai Public Health Clinical Center, Shanghai, China | Observational Study (15) |
On-going | NCT04292340 |
| 8. | Convalescent Plasma from Recovered COVID-19 Donors | Institute of Liver and Biliary Sciences, New Delhi, India | Phase II (20) |
Completed | NCT04346446 |
| 9. | Convalescent Plasma Therapy on Critically ill Novel Coronavirus (COVID-19) Patients | Alkarkh Health Directorate-Baghdad. Iraq | Interventional study (49) |
Completed | NCT04441424 |
| 10. | Effectiveness of Convalescent Immune Plasma Therapy | Bagcilar Training and Research Hospital, Istanbul, Turkey | Interventional study (60) |
Completed | NCT04442958 |